Web4 okt. 2024 · Currently, MannKind is a Zacks Rank #4 (Sell) in the Medical – Biomedical and Genetics industry that ranks in the Bottom 29% of our Zacks Industry Rank. Over the last 60 days, no analysts have... WebMNKD Stock Price - MannKind Corp. is a biopharmaceutical company, which engages in the development and commercialization of therapeutic products and devices for those …
MannKind Corporation (MNKD) Stock Price, Quote & News
Web13 apr. 2024 · MannKind last announced its earnings results on February 23rd, 2024. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, missing analysts' consensus estimates of ($0.06) by $0.01. The business earned $36.06 million during the quarter, compared to analysts' expectations of $35.51 million. Web3 aug. 2024 · MannKind's second-quarter numbers clearly show that the company is hanging on by a thread. ... High-growth Stocks. Return. 212%. S&P Return. 101%. ... But that value-destroying strategy can't go ... song of the lark breton
Strength Seen in MannKind Corp. (MNKD), Stock Shoots up 74%
WebAt MannKind we offer a competitive total compensation package, health, vision, dental benefits, 401k matching program, and financial benefits including employee stock purchase program, quarterly ... WebExpectations were high when Sanofi started marketing MannKind’s Afrezza early last year. But sales were so poor that Sanofi walked away from their marketing rights in early … Web31 mrt. 2024 · Over the last 12 months, MannKind's shares have ranged in value from as little as $2.61 up to $5.7299. A popular way to gauge a stock's volatility is its "beta". … song of the lark summary chapter 1